Avadel Pharmaceuticals plc (AVDL)
NASDAQ: AVDL · Real-Time Price · USD
15.66
+0.25 (1.62%)
At close: Sep 17, 2025, 4:00 PM EDT
15.66
0.00 (0.00%)
After-hours: Sep 17, 2025, 4:34 PM EDT
Avadel Pharmaceuticals Revenue
Avadel Pharmaceuticals had revenue of $68.13M in the quarter ending June 30, 2025, with 64.15% growth. This brings the company's revenue in the last twelve months to $221.08M, up 132.35% year-over-year. In the year 2024, Avadel Pharmaceuticals had annual revenue of $169.12M with 504.79% growth.
Revenue (ttm)
$221.08M
Revenue Growth
+132.35%
P/S Ratio
6.84
Revenue / Employee
$1,175,931
Employees
188
Market Cap
1.52B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 169.12M | 141.15M | 504.79% |
Dec 31, 2023 | 27.96M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | 22.33M | -36.88M | -62.28% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
AVDL News
- 1 day ago - Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding - GlobeNewsWire
- 5 days ago - Avadel: LUMRYZ Momentum And Pipeline Expansion Support Buy Rating - Seeking Alpha
- 7 days ago - Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 8 days ago - Avadel Pharmaceuticals Plc (AVDL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 12 days ago - Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025 - GlobeNewsWire
- 14 days ago - Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd - GlobeNewsWire
- 19 days ago - Avadel Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Avadel Pharmaceuticals plc (AVDL) Q2 2025 Earnings Call Transcript - Seeking Alpha